1 Mur ray CJ，Vos T，Lozano R，et al. Disabilityadjusted

life years (DALYs) for 291 diseases and

injuries in 21 regions，1990-2010：a systematic

analysis for the Global Burden of Disease Study

2010[J]. Lancet，2012，380：2197-2223.

2 Feigin VL，Forouzanfar MH，Krishnamurthi R，et

al. Global and regional burden of stroke during 1990-

2010：findings from the Global Burden of Disease

Study 2010[J]. Lancet，2014，383：245-254.

3 GBD 2013 DALYs and HALE Collaborators，Murray

CJ，Barber RM，et al. Global，regional，and national

disability-adjusted life years (DALYs) for 306

diseases and injuries and healthy life expectancy(HALE) for 188 countries，1990-2013：quantifying

the epidemiological transition[J]. Lancet，2015，386：

2145-2191.

4 Yang G，Wang Y，Zeng Y，et al. Rapid health

transition in China，1990-2010：findings from the

Global Burden of Disease Study 2010[J]. Lancet，2013，

381：1987-2015.

5 Jiang B，Wang WZ，Chen H，et al. Incidence and

trends of stroke and its subtypes in China：results

from three large cities[J]. Stroke，2006，37：63-68.

6 Hill MD，Kenney C，Dzialowski I，et al. Tissue

Window in Stroke Thrombolysis study (TWIST)：a

safety study[J]. Can J Neurol Sci，2013，40：17-20.

7 Liao XL，Wang CX，Wang YL，et al. Implementation

and outcome of thrombolysis with alteplase 3 to 4.

5 h after acute stroke in Chinese patients[J]. CNS

Neurosci Ther，2013，19：43-47.

8 Wa h lg r en N，Ahmed N，Dáva l o s A，e t a l .

Thrombolysis with alteplase 3-4.5 h after acute

ischaemic stroke (SITS-ISTR)：an observational

study[J]. Lancet，2008，372：1303-1309.

9 Mar tins SC，Fr iedrich MA，Brondani R，et al.

Thrombolytic therapy for acute stroke in the elderly：

an emergent condition in developing countries[J]. J

Stroke Cerebrovasc Dis，2011，20：459-464.

10 Demaerschalk BM，Kleindorfer DO，Adeoye OM，et

al. Scientific rationale for the inclusion and exclusion

criteria for intravenous alteplase in acute ischemic

stroke：A statement for healthcare professionals from

the American Heart Association/American Stroke

Association[J]. Stroke，2016，47：581-641.

11 Jauch EC，Saver JL，Adams HP Jr，et al. Guidelines

for the early management of patients with acute

ischemic s t roke：a guidel ine for healthcare

professionals from the American Heart Association/

American Stroke Association[J]. Stroke，2013，44：

870-947.

12 The National Institute of Neurological Disorders and

Stroke rt-PA Stroke Study Group. Tissue plasminogen

activator for acute ischemic stroke[J]. N Engl J Med，

1995，333：1581-1587.

13 Yan XB，Zhang S，Lou M. Factors related to

therapeutic outcomes of intravenous thrombolysis in

stroke patients with different severity[J]. Zhejiang Da

Xue Xue Bao Yi Xue Ban，2015，44：54-60.

14 Wa ng X，Lo EH. Tr igger s and mediator s of

hemorrhagic transformation in cerebral ischemia[J].

Mol Neurobiol，2003，28：229-244.

15 D'Amelio M，Terruso V，Famoso G，et al. Early

and late mortality of spontaneous hemorrhagic

transformation of ischemic stroke[J]. J Stroke

Cerebrovasc Dis，2014，23：649-654.

16 The NINDS t-PA Stroke Study Group. Intracerebral

hemor rhage after intravenous t-PA therapy for

ischemic stroke[J]. Stroke，1997，28：2109-2118.

17 Demchuk AM，Tanne D，Hill MD，et al. Predictors

of good outcome after intravenous tPA for acute

ischemic stroke[J]. Neurology，2001，57：474-480.

18 The NINS t-PA Stroke Study Group. Generalized

efficacy of t-PA for acute stroke. Subgroup analysis

of the NINDS t-PA Stroke Trial[J]. Stroke，1997，28：

2119-2125.

19 IST-3 collaborative group，Sandercock P，Wardlaw

JM，et al. The benefits and harms of intravenous

thrombolysis with recombinant tissue plasminogen

activator within 6 h of acute ischaemic stroke (the

third international stroke trial [IST-3])：a randomised

controlled trial[J]. Lancet，2012，379：2352-2363.

20 Mazya M，Egido JA，Ford GA，et al. Predicting the

risk of symptomatic intracerebral hemorrhage in

ischemic stroke treated with intravenous alteplase：

safe Implementation of Treatments in Stroke (SITS)

symptomatic intracerebral hemorrhage risk score[J].

Stroke，2012，43：1524-1531.

21 Saposnik G，Fang J，Kapral MK，et al. The iScore

predicts effectiveness of thrombolytic therapy for

acute ischemic stroke[J]. Stroke，2012，43：1315-1322.

22 Lou M，Safdar A，Mehdi rat ta M，et a l. The

HAT Score：a simple grading scale for predicting

hemorrhage after thrombolysis[J]. Neurology，2008，

71：1417-1423.

23 Br o t t T，Ad ams H P J r，Ol i nge r CP，e t a l .

Measurements of acute cerebral infarction：a clinical

examination scale[J]. Stroke，1989，20：864-870.

24 Saposnik G，Reeves MJ，Johnston SC，et a l.

Predicting clinical outcomes after thrombolysis using

the iScore：results from the Virtual International

Stroke Trials Archive[J]. Stroke，2013，44：2755-2759.

25 Fischer U，Baumgartner A，Arnold M，et al. What is

a minor stroke?[J]. Stroke，2010，41：661-666.

26 Khatri P，Conaway MR，Johnston KC，et al. Ninetyday

outcome rates of a prospective cohor t of

consecutive patients with mild ischemic stroke[J].

Stroke，2012，43：560-562.

27 Smith EE，Fonarow GC，Reeves MJ，et al. Outcomes

in mild or rapidly improving stroke not treated with

intravenous recombinant tissue-type plasminogen

activator：findings from Get With The Guidelines-

Stroke[J]. Stroke，2011，42：3110-3115.

28 Nedeltchev K，Schwegler B，Haefel i T，et al.

Outcome of stroke with mild or rapidly improving

symptoms[J]. Stroke，2007，38：2531-2535.

29 Rajajee V，Kidwell C，Starkman S，et al. Early MRI

and outcomes of untreated patients with mild or

improving ischemic stroke[J]. Neurology，2006，67：

980-984.

30 Barber PA，Zhang J，Demchuk AM，et al. Why are

stroke patients excluded from TPA therapy? An

analysis of patient eligibility[J]. Neurology，2001，56：

1015-1020.

31 Kim JT，Park MS，Chang J，et al. Proximal arterial

occlusion in acute ischemic stroke with low NIHSS

scores should not be considered as mild stroke[J].

PLoS One，2013，8：e70996.

32 Ferrari J，Knoflach M，Kiechl S，et al. Early clinical

worsening in patients with TIA or minor stroke：the

Austrian Stroke Unit Registry[J]. Neurology，2010，74：

136-141.

33 National Institute of Neurological Disorders Storke

rt-PA Stroke Study Group. Recombinant tissue

plasminogen activator for minor strokes：the National

Institute of Neurological Disorders and Stroke rt-PA

Stroke Study experience[J]. Ann Emerg Med，2005，

46：243-252.

34 Logallo N，Kvistad CE，Naess H，et al. Mild

stroke：safety and outcome in patients receiving

thrombolysis[J]. Acta Neurol Scand Suppl，2014，129：

37-40.

35 Greisenegger S，Seyfang L，Kiechl S，e t a l .

Thrombolysis in patients with mild stroke：results

from the Austrian Stroke Unit Registry[J]. Stroke，

2014，45：765-769.

36 Hassan AE，Hassanzadeh B，Tohidi V，et al. Very

mild stroke patients benefit from intravenous tissue

plasminogen activator without increase of intracranial

hemorrhage[J]. South Med J，2010，103：398-402.

37 Steffenhagen N，Hill MD，Poppe AY，et al. Should

you thrombolyse all or any stroke patients with baseline

National Institutes of Health stroke scale scores ＜ or

=5?[J]. Cerebrovasc Dis，2009，28：201-202.

38 Köhrmann M，Nowe T，Huttner HB，et al. Safety and

outcome after thrombolysis in stroke patients with

mild symptoms[J]. Cerebrovasc Dis，2009，27：160-

166.

39 Baumann CR，Baumgartner RW，Gandjour J，et al.

Good outcomes in ischemic stroke patients treated

with intravenous thrombolysis despite regressing

neurological symptoms[J]. Stroke，2006，37:1332-1333.